Milk Thistle English Version

CONTENT01 What is Milk thistle 03 Protects your liver 06 Boost Immune system 07 May protect against cancer 10 Prevent age-related decline in brain functions 11 Helps control / prevent diabetes 13 Lower high cholesterol 14 Help prevent gallstones 15 Anti-aging 17 Support bone health



2 | what is milk thistle

protects your liver | 3

4 | protects your liver

protects your liver | 5

6 | boost immune system

may protect against cancaer | 7

8 | boost immune system

boost immune system | 9

10 | prevent age-related decline in brain functions

helps control / prevent diabetes | 11

12 | prevent age-related decline in brain functions

lower high cholesterol | 13

14 | help prevent gallstones

anti-aging | 15

16 | anti-aging

support bone health | 17

References 1. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010 Oct;24(10):1423-32. 2. Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Dis- ease: A Marriage of Many Years. Molecules. 2017 Jan 24;22(2):191. 3. Ward J, Kapadia K, Brush E, Salhanick SD. Amatoxin poisoning: case reports and review of current therapies. J Emerg Med. 2013 Jan;44(1):116-21. 4. Polachi N, Bai G, Li T, Chu Y, Wang X, Li S, Gu N, Wu J, Li W, Zhang Y, Zhou S, Sun H, Liu C. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review. Eur J Med Chem. 2016 Nov 10;123:577-595. 5. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, Esquivel-So- to J, Esquivel-Chirino C, García-Luna Y González-Rubio M, Gayosso-de-Lucio JA, Morales-González JA. Hepatoprotective effect of silymarin. World J Hepatol. 2014 Mar 27;6(3):144-9. 6. I.A. Alhidary, Z. Rehman, R.U. Khan, M. Tahir. (2017) Anti-aflatoxin activ- ities of milk thistle (Silybum marianum) in broiler. World’s Poultry Science Journal 73:3, pages 559-566. 7. Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Med Sci Monit. 2002 Nov;8(11):BR439-43. PMID: 12444368. 8. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29(3):447-463. doi:10.1007/s10555-010-9237-0 9. Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Sily- bum marianum). Integr Cancer Ther. 2007 Jun;6(2):104-9. 10. Raina K, Kumar S, Dhar D, Agarwal R. Silibinin and colorectal cancer che- moprevention: a comprehensive review on mechanisms and efficacy. J Biomed Res. 2016;30(6):452-465. 11. Bosch-Barrera J, Queralt B, Menendez JA. Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treat Rev. 2017 Jul;58:61-69. 12. Vue B, Chen QH. The Potential of Flavonolignans in Prostate Cancer Man- agement. Curr Med Chem. 2016;23(34):3925-3950. 13. Imai-Sumida M, Chiyomaru T, Majid S, Saini S, Nip H, Dahiya R, Tanaka Y, Yamamura S. Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget. 2017 Sep 8;8(54):92032- 92042. 14. Borah A, Paul R, Choudhury S, Choudhury A, Bhuyan B, Das Talukdar A, Dutta Choudhury M, Mohanakumar KP. Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of ac- tion. CNS Neurosci Ther. 2013 Nov;19(11):847-53.

15. Galhardi F, Mesquita K, Monserrat JM, Barros DM. Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain. Food Chem Toxicol. 2009 Oct;47(10):2655-60. 16. Murata N, Murakami K, Ozawa Y, Kinoshita N, Irie K, Shirasawa T, Shimizu T. Silymarin attenuated the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer’s disease mouse model. Biosci Biotechnol Biochem. 2010;74(11):2299-306. 17. Kumar J, Park KC, Awasthi A, Prasad B. Silymarin extends lifespan and reduces proteotoxicity in C. elegans Alzheimer’s model. CNS Neurol Disord Drug Targets. 2015;14(2):295-302. 18. Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006 Dec;20(12):1036-9. 19. Kazazis CE, Evangelopoulos AA, Kollas A, Vallianou NG. The therapeutic potential of milk thistle in diabetes. Rev Diabet Stud. 2014 Summer;11(2):167-74. 20. Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. Silymarin in Type 2 Di- abetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Diabetes Res. 2016;2016:5147468. 21. Guo Y, Wang S, Wang Y, Zhu T. Silymarin improved diet-induced liver dam- age and insulin resistance by decreasing inflammation in mice. Pharm Biol. 2016 Dec;54(12):2995-3000. 22. Mulrow C, Lawrence V, Jacobs B, et al. Milk Thistle: Effects on Liver Disease and Cirrhosis and Clinical Adverse Effects: Summary. 2000. 23. Katiyar SK, Meleth S, Sharma SD. Silymarin, a flavonoid from milk thistle (Silybum marianum L.), inhibits UV-induced oxidative stress through targeting infil- trating CD11b+ cells in mouse skin. Photochem Photobiol. 2008;84(2):266-271. 24. Liu W, Li Y, Zheng X, Zhang K, Du Z. Potent inhibitory effect of silibi- nin from milk thistle on skin inflammation stimuli by 12-O-tetradecanoylphor- bol-13-acetate. Food Funct. 2015 Dec;6(12):3712-9. 25. Pizzorno J. Glutathione!. Integr Med (Encinitas). 2014;13(1):8-12. 26. Kim JL, Kim YH, Kang MK, Gong JH, Han SJ, Kang YH. Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-in- duced osteoporosis. Biomed Res Int. 2013;2013:919374. 27. El-Shitany NA, Hegazy S, El-Desoky K. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinyl- estradiol in ovariectomized rats. Phytomedicine. 2010 Feb;17(2):116-25. 28. Mohd Fozi NF, Mazlan M, Shuid AN, Isa Naina M. Milk thistle: a future potential anti-osteoporotic and fracture healing agent. Curr Drug Targets. 2013 Dec;14(14):1659-66.